DriveRank: Discovering Patient-Specific Driver Mutations

Sep 5, 2023

Friday, April 6, 2012 • 2:30-2:45 PM

Authors: Jack Pu Hou*, Pratik Lahiri, and Jian Ma

One of the pressing challenges in cancer genomics is to distinguish driver mutations (i.e. mutations involved in tumorigenesis) and passenger mutations (i.e. functionally neutral mutations). Current approaches to identifying driver mutations in cancer look for recurrent events in multiple samples. However, it is now acknowledged that individual tumors of the same type are highly heterogeneous and have diverse genomic alterations. We developed a novel method, called DriveRank, to discover patient-specific molecular driver events. Our probabilistic model accounts for both gene interactions and somatic mutations, which allow us to quantitatively rank a list of mutations in any individual tumor based on mutations propensity to become advantageous alterations. DriveRank was applied to Glioblastoma, Ovarian Cancer, and Breast Cancer data from The Cancer Genome Atlas, and it was shown to rank proposed driver mutations from other predictive software accurately by displaying a median rank for candidate mutations to be over the 92 percentile for all three cancers. Our results showed that the usual suspects (TP53, EGFR, RB1, APC, etc..) appeared frequently along with rarer, yet functionally important, suspects not normally classified as drivers. The DriveRank method will potentially enable the determination the optimal treatment strategy for patients through individualized assessment.